Feb 2, 2021
Russia's Sputnik V COVID-19 vaccine 91.6% effective in phase-3 trial – Reuters
The Sputnik V coronavirus vaccine developed in Russia showed an effectiveness rate of 91.6% in the phase-3 trial, Reuters reported on Tuesday, citing
了解更多
Next